TerminatedPhase 2NCT04800562
A Clinical Trial to Evaluate PCS499 in Treating Ulcerations in Patients Who Have Necrobiosis Lipoidica
Studying Necrobiosis lipoidica
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Processa Pharmaceuticals
- Principal Investigator
- Sian Bigora, PharmDProcessa Pharmaceuticals
- Intervention
- PCS499(drug)
- Enrollment
- 4 target
- Eligibility
- 18-80 years · All sexes
- Timeline
- 2021 – 2023
Study locations (4)
- Processa Clinical Site, San Diego, California, United States
- Processa Clinical Site, Rochester, Minnesota, United States
- Processa Clinical Site, Charleston, South Carolina, United States
- Processa Clinical Site, Milwaukee, Wisconsin, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04800562 on ClinicalTrials.gov